Skip to main content
Vistin Pharma logo

Vistin Pharma — Investor Relations & Filings

Ticker · VISTN ISIN · NO0010734122 LEI · 5967007LIEEXZXFQY092 OL Manufacturing
Open in API
Filings indexed 519 across all filing types
Latest filing 2020-05-28 Director's Dealing
Country NO Norway
Listing OL VISTN

About Vistin Pharma

https://www.vistin.com/

Vistin Pharma is a pharmaceutical company specializing in the production of Metformin Hydrochloride, an Active Pharmaceutical Ingredient (API). The company operates as a pure-play, global supplier, providing high-quality Metformin to pharmaceutical companies worldwide. In addition to the standard API, Vistin Pharma offers specialized grades such as Direct Compressible (DC) Metformin. With over 50 years of experience, the company emphasizes sustainable manufacturing from its dedicated European production facility.

Recent filings

Filing Released Lang Actions
Vistin Pharma ASA - flaggemelding
Director's Dealing Classification · 98% confidence The document text is very short (327 characters) and reports a transaction involving shares purchased by an entity (Pactum AS) where a board member (Espen Marcussen) holds a key position (CEO). This clearly indicates a report of personal share transactions by company directors or executives, which aligns with the definition of Director's Dealing (DIRS). The Norwegian term 'flaggemelding' translates to a notification of significant shareholding or insider trading, confirming this classification.
2020-05-28 Norwegian
Vistin Pharma ASA: Mandatory notification of trade
Director's Dealing Classification · 100% confidence The document explicitly states 'Mandatory notification of trade' and details a purchase of shares by a 'primary insider' (Commercial Director). This directly corresponds to the definition of reporting personal share transactions by company directors and executives, which is classified as Director's Dealing (DIRS). The short length (406 chars) confirms it is a notification, not a comprehensive report.
2020-05-22 English
Vistin Pharma ASA - aksjekjøp
Director's Dealing Classification · 98% confidence The document text is very short (330 characters) and announces a transaction where 'Intertrade Shipping AS' bought 1,100,000 shares in Vistin Pharma ASA, resulting in them owning 20.6% of the outstanding shares. This describes a personal share transaction by an entity closely related to management/directors (family-owned entity increasing stake), which falls under insider trading or director's dealing. The most appropriate category is 'Director's Dealing' (DIRS). It is not a general regulatory filing (RNS) because it is highly specific to insider transactions.
2020-05-20 Norwegian
Ex dividend NOK 1 today
Notice of Dividend Amount Classification · 100% confidence The document text is extremely short (151 characters) and announces a specific financial event: a dividend going ex-dividend ('Ex dividend NOK 1 today'). This directly corresponds to the definition of a Notice of Dividend Amount (DIV), which covers the announcement of dividend details. It is not a comprehensive report, a transcript, or a management change.
2020-05-20 English
Disclosure of large shareholding and mandatory notification of trade in Vistin Pharma ASA
Director's Dealing Classification · 98% confidence The document explicitly details a transaction in shares by a board member (Øystein Stray Spetalen) and associated companies, including the number of shares sold and the resulting ownership percentage (10.36%). This directly corresponds to the definition of 'Director's Dealing' (insider trades) or a notification of a change in significant shareholding. Since the transaction involves a director/insider, the most specific category is 'Director's Dealing' (DIRS). It is not a general major shareholding notification (MRQ) unless the threshold crossed was purely based on the resulting holding, but the focus on the director's trade makes DIRS more appropriate. The document length is very short (472 chars), but it is a substantive disclosure, not an announcement *about* another report, so RPA/RNS is not the primary choice.
2020-05-19 English
Vistin Pharma ASA - aksjekjøp
Major Shareholding Notification Classification · 95% confidence The document text is very short (330 characters) and announces a transaction where 'Intertrade Shipping AS' bought 4,025,000 shares in Vistin Pharma ASA, resulting in them owning 18.1% of the outstanding shares. This clearly describes a transaction in the company's own shares or a significant change in share ownership by an insider/related party. Given the options, 'Transaction in Own Shares' (POS) covers share repurchases/issuance, but 'Major Shareholding Notification' (MRQ) is specifically for changes in significant share ownership levels crossing thresholds (18.1% is significant). However, the text reads like a direct notification of an insider/related party transaction rather than a formal regulatory filing about crossing a threshold, which often falls under Director's Dealing (DIRS) if the buyer is a director, or MRQ if it's just a major shareholder notification. Since the text explicitly details the resulting ownership percentage (18.1%) after a purchase by an entity related to the family, MRQ (Major Shareholding Notification) is the most precise fit for reporting a change in significant ownership, although DIRS might apply if the family is deemed insiders. Given the focus on the resulting percentage ownership, MRQ is selected over DIRS or POS.
2020-05-19 Norwegian

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.